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Fatty acidElectronic circular dichroism (ECD), absorption and ﬂuorescence spectroscopy were used to study the
enantioselective interactions which involved bilirubin (BR), liposomes, human serum albumin of two different
purities, pure (HSA) and non-puriﬁed of fatty acids (FA-HSA), and individual fatty acids.
The application of the ECD technique to such a complex problemprovided a newperspective on the BRbinding to
liposomes. Our results demonstrated that in the presence of pure HSA, BR preferred to bind to the protein
over the liposomes. However, in the presence of FA-HSA, BR signiﬁcantly bound to the liposomes composed
either of DMPC or of sphingomyelin and bound only moderately to the primary and secondary binding sites of
FA-HSAeven at highBR concentrations. For theDMPC liposomes, even a changeof BR conformation uponbinding
to the primary binding site was observed. The individual saturated fatty acids inﬂuenced the BR binding to HSA
and liposomes in a similar way as fatty acids from FA-HSA. The unsaturated fatty acids interacted with BR alone
and prevented it from interacting with either 99-HSA or the liposomes. In the presence of arachidonic acid, BR
interacted enantioselectively with the liposomes and only moderately with 99-HSA.
Hence, our results show a substantial impact of the liposomes on the BR binding to HSA. As a consequence of the
existence of fatty acids in the blood plasma and in the natural structure of HSA, BR may possibly bind to the cell
membranes even though it is normally bound to HSA.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Every day a certain amount of “old” blood cells is replaced by newly
produced ones. During this process, an orange-colored pigment biliru-
bin (BR) is formed as a product of the decomposition of the blood
pigment heme. BR is afterwards converted to a more water-soluble
form and is excluded from the body [1]. BR belongs to the group of
non-planar tetrapyrrolic pigments which form a helical spatial struc-
ture, with either a P- or M-sense of helicity [2–5] (Fig. 1). The racemiza-
tion barrier between these two forms is low, and because of this, the P-
and M-forms interconvert rapidly. Therefore, BR exists as a racemate in
a homogenous solution and also when it is unbound in the blood
plasma. Although there are several polar groups in the BR structure, itacid;BR, bilirubin;DLS,dynamic
phocholine; ECD, electronic cir-
minwith 4% of fatty acids; HSA,
, large unilamellar vesicle; MA,
cid; UV–Vis, ultraviolet–visible
nd Measurements, Institute of
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vá).behaves mostly as a nonpolar compound, because the polar groups
are intramolecularly connected with hydrogen bonds [2–5].
Although it is a waste product, BR fulﬁlls a wide range of biological
activities in the human body [1]. In the pathologic state, BR may accu-
mulate and at higher concentrations its negative effects may appear
[6–17]. Among themost discussed effects of BR are its deposition in tis-
sues and its inﬂuence on nerve cell membranes whichmay result in cell
disturbance.Moreover, BR binding to brain nerve cells is supposed to be
one of the main causes of BR encephalopathy in jaundiced newborns.
The interaction of BR with cells was previously studied both for model
situations and in physiological conditions [13–16,18–28]. It was found
that BR preferentially interacts enantioselectively with different
liposomic models of cell membranes [18–20,29]. This means that one
of the two enantiomeric forms (P- or M-form) of BR binds more to the
liposomes and because the two forms interconvert very rapidly, the
non-bound BR remains racemic. The enantiodiscrimination of BR on
the membranes is supposed to be one of the primary causes of the
described neurotoxic effects of BR. Because of the chiral nature of this
interaction, chiroptical techniques, electronic and vibrational circular
dichroism (ECD, VCD) were advantageously used to study bound BR
and its effects [18,29].
Under the normal conditions in the human body, BR should not be
dangerous to our well-being because it is mainly transported in the
Fig. 1. Spatial structure of the M- and P-forms of BR with the dihedral angle estimated for
BR in aqueous solution. (A) The negative couplet (spectral shape composed of two
neighboring bands of opposite signs, negative band being at a higher wavelength than
the positive) and positive couplet observed typically in the ECD spectra for the M- and
P-forms of BR, respectively. (B) A simulation of the inﬂuence of the dihedral angle in the
BR structure on the ECD spectra estimated with the exciton coupling method (ref. [26]),
note a shift of the couplet position and the decrease of its intensity. (C) A simulated
spectral overlap possible for the ECD spectra of the M- and P-forms of BR with different
dihedral angles in their structure.
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dant carrier proteins. The HSA structure is comprised of three domains,
each of which consists of subdomains. The protein has extensive bind-
ing possibilities for different drugs, drug-analogs, hormones, steroids
and small molecules, and also works as a main transporter of fatty
acids (FAs) in the blood plasma. FAs are in fact primary ligands for
HSA and at least seven different binding sites of FAs were described in
the HSA structure [30–33] with very diverse binding afﬁnities [34]. BR
has three potential binding sites in the structure of HSA: one primary
site located in subdomain IIA of HSA with a considerably high binding
constant (Ka ~ 108M−1) and two secondary sites located in subdomains
IB and IIIA with lower and similar binding constants (Ka ~ 106 M−1)
[35–39]. Remarkably, BR preferentially binds in its P-form to all three
binding sites of HSA [35,36,39–43]. It should be noted here that due to
the difference in the binding constants, the binding to the secondary
sites occursmostly after the primary site has been saturated. Sowe can-
not observe the binding to the secondary sites alone unless the primary
site is blocked by another compound.
Our study is aimed at the situations that may arise on the molecular
level in the human body both during standard and pathologic states. As
the enantioselective interaction of BR with liposomic models of mem-
branes was conﬁrmed [18,29], our present study focuses on the ternary
systems of BR with liposomes and HSA. The object of our study is, ﬁrst,
whether BR will bind to the liposomes even in the presence of HSA, for
which it has a high binding constant, and, second, what would occur at
increased concentrations of BR when some of the HSA binding sites
would be occupied by BR or by other compounds. Previous studies
[44,45] showed that the tendency of BR to bind to HSA is mostly higher
than to liposomes, but they proved a strong dependence on the ambient
conditions and liposome composition.
Hence, we studied the inﬂuence of HSA on the BR interactions with
liposomes composed of 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC, a model of ordinary cells) and of sphingomyelin (a model of
nerve cells). These two types of liposomes were chosen, because they
serve as an appropriate model of natural membranes [29]. Our previous
study [29] also showed a negligible effect of cholesterol on the interac-
tions of the selected liposomes with BR and, therefore, cholesterol was
not included in this study. Only a few tests were run for each studied
system to conﬁrm that its presence did not inﬂuence the systems with
the FAs and serum albumins used.As it is mainly unbound free BR, the effects of which are neurotoxic,
and because its concentration is strongly inﬂuenced by the binding
capacity of HSA, two different HSAs were tested: one pure and one
non-puriﬁedwith bound FAs, which is supposed to have different bind-
ing afﬁnities for BR. HSA does not only work as an FA transporter in the
blood plasma [32,34,46,47] but FAs bound to HSA were found to play a
signiﬁcant role duringmany tasks of this protein especially in the case of
drug treatment [32,34,48,49] and renal tubulointerstitial injury [50].
Additionally, even in the presence of liposomes or FA-incubated lipo-
somes a preferential binding of FAs to HSA was observed [51,52].
Hence it is truly important to study the equilibrium in the BR/HSA/
liposome system not only with pure HSA but also with albumin which
was isolated from the blood plasma and which was not puriﬁed of FAs.
FAs are well-known to inﬂuence the binding capacity of HSA being
its natural components and they can also transport from HSA to lipo-
somes and vice-versa [39,51–57]. The effect of six different FAs and
their mixtures was studied separately as an addition to the pure HSA
solution. Since two thirds of FAs bound to HSA in the blood plasma are
unsaturated under normal circumstances, the most common being
oleic (OA), linoleic (LA) and arachidonic acid (AA), these three acids
were selected as representatives for unsaturated FAs. For saturated
FAs, the three most common FAs in the blood plasma were chosen:
myristic (MA), palmitic (PA), and stearic acid (SA).
As the major method to study the described systems, the ECD spec-
troscopy was chosen. It enables the study of different chiral forms of
bound BR (Fig. 1) and of changes in the secondary and tertiary struc-
tures of HSA as the spectral bands of HSA are in different positions
from BR. The spectroscopy also enables a differentiation between BR
bound to the liposomes and HSA manifested as different values of
molar ellipticity and shifts in couplet positions. The spectra are also
very sensitive to the changes of the dihedral angle in the BR structure
(Fig. 1B). The ECD method was complemented by the UV–Vis absorp-
tion spectroscopy and by the ﬂuorescence emission.
2. Materials and methods
2.1. Materials
The lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
and sphingomyelinwere purchased fromAvanti Polar Lipids (Alabaster,
AL). Bilirubin-IXa (BR) was purchased from Frontier Scientiﬁc (USA).
Human serum albumin (99% A3782 and 96% A1653), palmitic acid
(PA), myristic acid (MA), stearic acid (SA), linoleic acid (LA), oleic acid
(OA) and arachidonic acid (AA) were purchased from Sigma Aldrich.
All of the chemicals were used without further puriﬁcation.
2.2. Preparation of large unilamellar vesicles
The liposomes were prepared using the standard procedures [58].
The appropriate amount of dried lipid was weighed and dissolved in a
chloroform/methanol mixture (2:1, v/v) and vortexed for 10 min. The
sample was dried under low pressure to form a thin ﬁlm on the vial
wall, after which it was left under high vacuum for 5 h. The ﬁlm was
then hydrated via the addition of a 2 × 10−2 M phosphate buffer
(pH = 7.4) and vortexed extensively for 15 min. The resulting
multilamellar liposome suspension was then reduced to uniform large
unilamellar vesicles (LUVs) by passing twenty-three times through a
polycarbonate membrane with a mean pore diameter of 100 nm using
a Mini-Extruder (Avanti Polar Lipids). After extrusion, the LUVs were
allowed to equilibrate for at least 2 h before use. The ﬁnal lipid concen-
tration was calculated based on the weight of the dried lipid [59–63].
The dynamic light scattering (DLS) method conﬁrmed the narrow size
distribution of the LUVs with the maximum at approximately (110 ±
3) nm for both the DMPC and sphingomyelin liposomes.
For the testing of the scattering effects, larger liposomes (212±11)nm
and (415± 12) nmwere prepared by extrusion and smaller liposomes
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by sonication.
2.3. Preparation of fatty acid solutions
The appropriate amount of FA was weighed, dissolved in chloro-
form, and vortexed for 15 min in a vial. The sample was then dried
under low pressure to form a thin ﬁlm on the vial wall, after which it
was left under high vacuum for 4 h. The ﬁlm was then hydrated with
a 1 × 10−3 M solution of HSA in 2 × 10−2 M phosphate buffer (pH =
7.4) and vortexed and sonicated extensively for 80 min at 30 °C. The
resulting opalescent solution was used as a bulk solution of FA and
HSA. The possible effect of the procedure on the structure of HSA was
inspected and found to be non-observable.
2.4. Sample preparation
The solution of a BR sodium salt (concentration 0.005 M) was
prepared to achieve a higher solubility of BR [64]. Powdered BRwas dis-
solved in a 3:1 molar excess of a sodium hydroxide aqueous solution so
that a complete neutralization was achieved and the solution was cen-
trifuged to conﬁrm the complete dissolution of BR. This solution was
used as a stock solution but for no longer than 2 h and during that
timewas stored in the dark and in a refrigerator. The spectral measure-
ments were conducted in solutions of a 2 × 10−2 M phosphate buffer
(pH = 7.4).
For the ECD and UV–Vis absorption measurements, the BR concen-
tration was in the range of 1 × 10−5–5 × 10−5 M. The concentration
of the DMPC and sphingomyelin was 1 × 10−3 M. The concentration
of serum albumin was in the range of 2 × 10−6–1 × 10−5 M. The con-
centration of FA was 1 × 10−4 M. For the ﬂuorescence emission mea-
surements, the BR concentration was 1 × 10−5 M, the concentration
of the DMPC and SPM liposomes was 1 × 10−3 M, and HSA concentra-
tionwas 1 × 10−5 M. All themeasured solutions did not show the pres-
ence of precipitates as was conﬁrmed by their centrifugation.
2.5. Electronic circular dichroism, ﬂuorescence emission and UV–Vis
absorption
The ECD, ﬂuorescence emission andUV–Vis absorption spectra were
measured on a J-810 spectrometer equipped with a ﬂuorescence acces-
sory FDCD-404L (Jasco, Japan). The ECD and UV–Vis absorption spectra
were measured in a quartz cuvette with an optical path length of 1 cm
or 1 mm (Helma, Germany). The conditions of the measurements
were as follows for the region of BR absorption: a spectral region of
250–600 nm, a scanning speed of 100 nm/min, a response time of 1 s,
a resolution of 1 nm, a bandwidth of 1 nm and a sensitivity of
100 mdeg; for the region of protein absorption: a spectral region of
200–300 nm a scanning speed of 5 nm/min, a response time of 16 s, a
resolution of 0.5 nm, a bandwidth of 1 nm and a sensitivity of
100 mdeg. The ﬁnal spectrumwas obtained as an average of 5 accumu-
lations in both cases. Spectra are presented in molar ellipticity units
relative to the concentration of BR.
The conditions of the ﬂuorescence emission measurements were as
follows: a spectral region of 460–800 nm, an excitation wavelength of
435 nm, a response time of 2 s, a resolution of 1 nm, a bandwidth of
10 nm and a sensitivity of 900 V. The ﬁnal spectrum was obtained as
an average of 5 accumulations. The spectra were corrected for the
inner ﬁlter effect according to ref. [65].
All the measurements were conducted at room temperature (25 °C).
Liposomes of different sizes were tested (Section 2.2) to ﬁndwheth-
er there is a spectral distortion in the ECD spectra caused by the scatter-
ing from the particles. No size-related effects were observed for the
tested liposomes up to 110 nm. The 110 nm liposomes were conse-
quently used in all the measurements because of their narrow size dis-
tribution due to extrusion. For the (212 ± 11) and (415 ± 12) nmliposomes, high spectral noise accompanied with smaller distortion of
the ECD bands was observed suggesting scattering effects.
3. Results and discussion
In the ﬁrst part of the study, BR binding to 99% pure HSA (further
called 99-HSA) and to 96% pure HSA which was not puriﬁed of FAs
(hereinafter referred to as FA-HSA) andmodelmembraneswas studied.
For the molecular systems composed of BR and 99-HSA, the spectral
characteristics of the BR binding to HSA with and without model mem-
branes were gained. On the other hand, the more complex molecular
system with FA-HSA represented model with biological relevance.
In the second part, different FAs were added to the ternary system BR/
99-HSA/model membranes at the FA:HSA ratio 10:1.
All the spectra were measured after the equilibrium was reached
and therefore kinetic processes should play no role in the obtained re-
sults. Measurements were done for low BR concentrations similar to
physiological in the blood plasma and for the BR:lipid ratio 1:100. This
ratio was used to simulate locally increased concentrations of lipids
when BR is found near the cell wall. The spectra were measured for
the solutions of BR into which the liposomes were added ﬁrst and
then, after the equilibrium was reached, HSA was added. The results
obtained for the inverse course of steps did not differ considerably.
3.1. Bilirubin with 99-HSA or FA-HSA and model membranes
Figs. 2 and 3 show the ECD and UV–Vis absorption spectra obtained
for the BR mixtures with the DMPC or sphingomyelin liposomes and
with 99-HSA and FA-HSA, respectively. Fig. 2A summarizes the results
previously obtained by us for the BR/99-HSA system [42,43]. While
BR alone did not have an ECD signal because of its racemization, for
99-HSA or FA-HSA alone, a small negative band reﬂecting the tertiary
structurewas observed in the region of aromatic amino acid absorption.
BR alone had a very weak ﬂuorescence signal due to strong quenching
[66,67] and, hence, only ﬂuorescence signals of bound BR could be
observed (Fig. 4).
Because only boundBR is optically active, the observed similarmolar
ellipticity up to the 3:1 ratio for the BR/99-HSA mixture conﬁrmed the
chiral selection of the P-form of BR into three binding sites in HSA, one
primary and two secondary [42,43] (see Fig. S1 for the spectra in
[mdeg] and Fig. S2 for a reversed titration). As the high value of
Ka ~ 108 M−1 for the primary binding site indicates, more than 98% of
the BR molecules in the solution were bound. The absorption spectrum
of BR bound to the primary site was shifted to the red region in compar-
ison with the spectrum of unbound BR due to the change in the torsion
angle in the BR structure (Fig. 1)when bound andmaybe also due to the
changes in the polarity of the environment. For the ratios 2:1 and 3:1,
the UV–Vis spectra were closer to the blue region indicating a shift
due to different torsion angles between the secondary and primary
sites. The separation of the UV–Vis spectra to the components
(for details, see Section 7 of the Supplementary material) provided in-
formation about a presence of approximately 15% and 20% of unbound
BR, respectively. This corresponds with the lower binging constants to
the secondary binding sites. For the BR:99-HSA ratio greater than 3:1,
the decrease of molar ellipticity value evidenced the saturation of an
enantioselective binding of HSA towards BR.
In the case of FA-HSA (Fig. 3A, see Fig. S3 for the spectra in [mdeg]
and Fig. S4 for a reversed titration), a lower value of molar ellipticity
and continual decrease of signal suggested that the FAs present in the
FA-HSA sample inﬂuenced the BR binding to HSA and partly hampered
all three binding sites in the HSA structure. The binding possibilities of
BR were more limited in this system when compared with 99-HSA.
Separation of the UV–Vis spectra to the components led to the estima-
tion of 10% of unbound BR for the 1:1 ratio. This was conﬁrmed by
the lower intensity in the ﬂuorescence emission compared to BR with
99-HSA (Fig. 4).
Fig. 2. The ECD (top) and UV–Vis spectra (bottom) of BRwith 99-HSA (A) and in the presence of the DMPC (B) or sphingomyelin (SPM) liposomes (C)measured for the BR:99-HSA ratios
from 1:1 to 5:1. The spectra of 99-HSA (A), BR (all panels) and BRwith theDMPC (B) or sphingomyelin liposomes (C) are also shown. The concentration of 99-HSAwas 1 × 10−5M, that of
the liposomes 1 × 10−3 M and the BR concentration was given by the BR:99-HSA ratio and was in the region of 1 × 10−5 M–5 × 10−5 M.
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they recognized the same P-conformer [29], howeverwith a different po-
sition and intensity (Figs. 2B,C, 3B,C) than in the BR/HSA system. As theFig. 3. The ECD (top) and UV–Vis spectra (bottom) of BRwith FA-HSA (A) and in the presence o
from 1:1 to 5:1. The spectra of FA-HSA (A), BR (all panels) and BRwith theDMPC (B) or sphingo
the liposomes 1 × 10−3 M and the BR concentration was given by the BR:FA-HSA ratio and waposition and intensity of the BR couplet strongly depend on the dihedral
angle in the BR structure [68] (schematically shown in Fig. 1), we suppose
that the structure of BR interactingwith the liposomeswas different fromf the DMPC (B) or sphingomyelin (SPM) liposomes (C)measured for the BR:FA-HSA ratios
myelin liposomes (C) are also shown. The concentration of FA-HSAwas 1× 10−5M, that of
s in the region of 1 × 10−5 M–5 × 10−5 M.
Fig. 4. The ﬂuorescence emission spectra of BR with 99-HSA and FA-HSA and in the
presence of the DMPC or sphingomyelin (SPM) liposomes. The spectra of the ternary
mixture of BR/99-HSA/liposomes and BR/FA-HSA/liposomes are also shown. All the
spectra were measured for the BR:HSA ratio 1:1. The concentration of HSA and BR was
1 × 10−5 M and of the liposomes was 1 × 10−3 M.
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the couplet position and the shift observed in the ﬂuorescence spectra
also evidenced the inﬂuence of different polarity of the environment,
especially, in the case of the DMPC liposomes where BR bound deeper
into the bilayer [29].
The impact of the DMPC liposomes on the BR binding to 99-HSA and
FA-HSA was very different (cf. Figs. 2B and 3B). For the 1:1 BR:99-HSA
ratio, the minor spectral changes caused by the presence of DMPC
liposomes suggested that liposomes did not compete with the primary
binding site of 99-HSA. The analyses of the ﬂuorescence emission
spectra (for details, see Section 7 of Supplementary material and Table
S2) show only 10% and 8% of bound BR bound to the DMPC and
sphingomyelin liposomes, respectively. The UV–Vis spectra evidenced
similar results and only about 4% of unbound BR.
However, already for the BR:99-HSA ratio 2:1, the molar ellipticity
increased, both components of the couplet were broader and a shift of
the couplet position quoted in Fig. 2 was observed. Although the spec-
tral effects of the liposome presence are not very pronounced, it is
clear that at increased BR concentrations, which accompany several
pathologic states in the human body, competition between the second-
ary sites and liposomes occurred after the saturation of the primary
binding site, and BR bound to both 99-HSA and liposomes. Interestingly,
as the shifts in the UV–Vis spectra and their separation to the compo-
nents suggested, BR bound more to the DMPC liposomes than to the
sphingomyelin liposomes (~48 and ~44% of bound BR, respectively,
Table S1). For the higher ratios, an increase of the unbound BR was ob-
served as well as its binding to the liposomes.
In the case of FA-HSA, the presence of the DMPC liposomes caused a
distinctly different response already at BR:FA-HSA ratio 1:1 as is
depicted in Fig. 3B. The observed spectral pattern with a new presence
of a higher-wavelength negative band was probably a result of overlap-
ping couplets for the P- and M-forms of BR with different positions of
the couplets, which is usually an effect of different torsion angles in
the BR structure (ref. [68] and Fig. 1). This suggested that not only the
P-form but also theM-form of BR bound to FA-HSA. The possible expla-
nation might be that the presented FAs inﬂuenced the DMPC liposomes
and hence the M-form of BR bound onto them. However, the liposomes
prepared from DMPC, MA, PA and SA did not show any changes in theenantioselectivity of the BR binding (Fig. S5). Also, the same FAs
added to the BR solution with the DMPC liposomes did not change the
BR signal. This means that the inﬂuence of the DMPC liposomes and
FAs from FA-HSA led to changes in the HSA primary binding site so
that the M-form of BR also bound. Also the analysis of the ﬂuorescence
and UV–Vis spectra (Tables S1 and S2) provided ~27–32% of bound BR
bound to theDMPC liposomes, whichwasmore than three times higher
when compared to the 99-HSA system.
The differences in intensity for all ratios in comparison with the 99-
HSA system were connected to the effect of FAs from FA-HSA. They
probably blocked one or both of the secondary binding sites of HSA.
That supported more BR binding to the DMPC liposomes as was also
conﬁrmed by the separation of the UV–Vis absorption bands for the
higher ratios (approximately 63% for BR bound to the liposomes relative
to the secondary sites of FA-HSA for the 3:1 ratio).
The inﬂuence of the sphingomyelin liposomes is depicted in Figs. 2C
and 3C. For both 99-HSA and FA-HSA systems, the sphingomyelin lipo-
somes affected the binding of BR to HSA even at the ratio favoring the
primary binding site (~26% of bound BR bound to the liposomes, Tables
S1 and S2). As far as the secondary binding sites were concerned, BR
preferred to bind to the liposomes in the FA-HSA system more times
than in the 99-HSA system (~60% for FA-HSA and ~44% for 99-HSA of
BR bound to the liposomes Table S1). However, unlike the system
with the DMPC liposomes, no inversion of the BR conformation upon
binding was observed.
The obtained results indicated that FAs, which form an inherent part
of the HSA transporter in the human blood plasma, signiﬁcantly inﬂu-
enceHSA interactionwith BR andmay contribute to its binding tomem-
branes. Remarkably, BR signiﬁcantly bound to the sphingomyelin
liposomes at higher concentrations and even at the BR:HSA ratio 1:1
typical for the blood plasma. The combined effect of FAs from FA-HSA
and of the DMPC liposomes caused changes in the FA-HSA primary
binding site and supported more BR binding to the liposomes. This
means that especially at increased BR concentrations, BR would not
bind dominantly to HSA but would also bind to cell membranes, and
this may lead to damage of the cell structure.
All the describedmolecular systemswere tested also for a reversed ti-
tration (Figs. S2 and S4), which conﬁrmed the observations made above.
3.2. Bilirubin with 99-HSA, fatty acids and model membranes
As we have described in the previous part, the interactions in the
systemwith FA-HSA differed greatly from the systemwith 99-HSA indi-
cating the potential negative biological effects of BR on cell membranes.
Therefore, we tried to identify which of the most abundant FAs in the
blood plasma, three saturated and three unsaturated, had the biggest
impact. Since at least seven binding sites of FAs were described in the
structure of HSA [31,32], a 10:1 excess of FAs over HSA was used.
3.2.1. The effect of saturated fatty acids
The inﬂuence of MA, PA and SA and of their equimolar mixture was
studied. As the effect of each individual FA was similar, here we show
only the results obtained for PA (Fig. 5) and the mixture of PA, MA
and SA (Fig. 6).
The spectra reported in Fig. 5A depict the inﬂuence of PA on the BR
binding to 99-HSA without liposomes. The observed spectral pattern
for the BR:99-HSA ratio 1:1 (in accordance with ref. [69]) indicated
that in the presence of PA not only the P-form but also the M-form of
BR bound to the primary site of HSA. The couplets for the M- and P-
forms overlapped and the resulting signal did not have an apparent pos-
itive maximum (Fig. 1). Similar effects were also observed in the pres-
ence of MA and SA and themixture of saturated FAs (Figs. S6, S7 and 6).
For the increasing ratios, where the primary site and the secondary
sites might be involved, the P-form prevailed implying that the
enantioselectivity of the secondary binding sites was not gravely inﬂu-
enced. The UV–Vis spectra were shifted more to the red region in
Fig. 5. The ECD (top) andUV–Vis spectra (bottom) of BRwith PA and 99-HSA (A) and in the presence of the DMPC (B) or sphingomyelin (SPM) liposomes (C)measured for the BR:99-HSA
ratios from 1:1 to 5:1. The spectra of 99-HSA with BR (ratio 1:1, all panels), 99-HSA with PA (A) and with the DMPC (B) or sphingomyelin (SPM) liposomes (C) are also shown. The
concentration of 99-HSA was 1 × 10−5 M, that of PA 1 × 10−4 M, that of the liposomes 1 × 10−3 M and the BR concentration was given by the BR:99-HSA ratio and was in the region
of 1 × 10−5 M–5 × 10−5 M.
Fig. 6. The ECD (top) and UV–Vis spectra (bottom) of BR with PA, MA, and SA mixture (1:1:1) and 99-HSA (A) and in the presence of the DMPC (B) or sphingomyelin (SPM)
liposomes (C) measured for the BR:99-HSA ratios from 1:1 to 5:1. The spectra of 99-HSA with BR (ratio 1:1, all panels), 99-HSA with PA, MA, and SA mixture (1:1:1) (A) and with the
DMPC (B) or sphingomyelin (SPM) liposomes (C) are also shown. The concentration of 99-HSA was 1 × 10−5 M, that of the liposomes 1 × 10−3 M and the BR concentration was
given by the BR:99-HSA ratio and was in the region of 1 × 10−5 M–5 × 10−5 M. The total concentration of FAs was 1 × 10−4 M.
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angles of the M-form of BR and due to the presence of FAs inﬂuencing
the polarity of the environment.
Interestingly, the molar ellipticity in this system was very low com-
pared to the systemwithout FAs (cf. Figs. 5 and 2); most likely, because
saturated FAs limited the binding possibilities of BR to all three binding
sites. This was conﬁrmed by the analysis of the UV–Vis spectra which
showed 10% and 31% of unbound BR for the 1:1 and 3:1 ratios, respec-
tively (Table S1). However, because each acid has a different chain
length, each of them caused a speciﬁc hindrance of the BR binding.
The molar ellipticity was the lowest for the shortest of the studied FAs
MA. The binding possibilities of MA in 99-HSA were greater and hence
it hampered the binding sites of 99-HSA more. This was also conﬁrmed
by the highest fraction of unbound BR 14% for the 1:1 ratio and by the
observed changes in the secondary structure of HSA which were
reﬂected in the 200–300 nm region of the ECD spectra. According to
our deconvolution of the spectra using CDNN software (developed by
Gerald Bohm of the University of Halle, Germany [70]), MA decreased
the apparent content of the α-helical conformation of 99-HSA more
than PA and SA (Table S3).
The system composed of the DMPC liposomes with PA is shown in
Fig. 5B and with the saturated FA mixture in Fig. 6B. The observed spec-
tra were similar to the FA-HSA system suggesting the binding of both
the P- and M-forms of BR to the primary site of 99-HSA. The low inten-
sity of the spectra indicated that the afﬁnity of FAs towards 99-HSAwas
higher than towards the liposomes [52,55,71,72] and they hindered part
of the primary sites of 99-HSA (~34% of BR bound to the DMPC lipo-
somes and only ~66% to the primary site, Table S2). The UV–Vis spectra
showed approximately 8% of unbound BR (Table S1).
The complex ECD spectral shape for higher ratios suggested an over-
lap of three spectral components: of the BR bound to the primary site, of
the BR bound to the secondary sites of 99-HSA, and of the BR bound to
the DMPC liposomes (a model summation of the components in
Fig. S8). The enantioselective binding to the secondary siteswas limited,
because the overall spectral intensity was very low — over 30% of un-
bound BR according to the analysis of the UV–Vis spectra. This indicated
a preference for the BR binding to the liposomes conﬁrmed also by the
UV–Vis spectra (~67% of bound BR was bound to the liposomes, Table
S1). Remarkably, this was observed to a greater extent in the system
with the saturated FA mixture than with individual FAs.
The situation for the sphingomyelin liposomeswith PA is depicted in
Fig. 5C, with the mixture of saturated FAs in Fig. 6C. For the BR:99-HSA
ratio 1:1, there was an indication of the M-form of BR bound to 99-HSA
but the P-form prevailed. With the increasing ratios, BR bound in the P-
form to the secondary sites of 99-HSA and also to the liposomes. All sat-
urated FAs caused a blue shift of the couplet for BR bound to 99-HSA, as
a result of the conformational change of boundBR,while they had no ef-
fect on the BR binding to the sphingomyelin liposomes (Fig. S5). Inter-
estingly, as the analyses of the UV–Vis spectra show, binding to the
sphingomyelin liposomes was even more pronounced in the systems
with MA and SA than with PA; ~66% for BR bound to the liposomes
for PA, 69% for MA and 65% for SA.
The combination of saturated FAs and also each individual saturated
FA strongly inﬂuenced BR binding to the primary site of 99-HSA for
which they changed the stereoselectivity of BR binding. They also limit-
ed the binding to the secondary sites probably due to their presence in
the sites [30,31,34]. This fact favored the BR binding to the liposomes
whichwas strongly evidenced for both types of liposomes. The obtained
spectra shared common features with the spectra obtained in the pres-
ence of FA-HSA indicating that saturated FAs play role during BR inter-
actions with serum albumin in the blood plasma and support BR
binding to the membranes.
3.2.2. The effect of unsaturated fatty acids
The impact of unsaturated FAs on the BR interactions with 99-HSA
both without and in the presence of the liposomes is demonstrated forAA in Fig. 7. In the system without liposomes, a very weak ECD signal
in the BR region was observed. Similar spectra were also observed in
the case of LA and OA (Fig. S9). Zero ﬂuorescence was also observed
for all three FAs. The BR racemate probably interacted with the unsatu-
rated FAs. This was demonstrated in the UV–Vis spectra (Figs. 7 and S9)
where a signiﬁcant band at 483 nmwas observed independently of the
presence of 99-HSA. This indicated nearly 100% of unbound BR. Hence,
the structure of BR was strongly affected by unsaturated FAs. The effect
on 99-HSA was minimal, which was observed in the spectral region
reﬂecting its tertiary (Figs. 7 and S9) and secondary structures (spectra
not shown).
In the presence of AA and the DMPC or sphingomyelin liposomes
(Figs. 7B and C), BR interacted enantioselectively. For both the lipo-
somes, the UV–Vis spectral band separation showed that BR bound
mostly to the liposomes (40% for the 1:1 and 70% for the 3:1 ratio)
and only slightly to 99-HSA. The UV–Vis spectral band at 483 nm was
not seen in the presence of liposomes. This means that free AA bound
to BR in the system without liposomes and disabled BR binding to 99-
HSA. Yet, in the presence of the liposomes, AA bound to the liposomes
and did not interact signiﬁcantly with BR. Hence, BR could bind to the
liposomes and alsomoderately tomainly the primary site of 99-HSA. In-
terestingly, the interaction of OA and LAwith BRwas stronger thanwith
the liposomes, so nearly no signal was observed in the ECD spectra
(Fig. S9).
3.2.3. Combined effect of saturated and unsaturated fatty acids
Fig. 8A shows that the combined effect of an equimolarmixture of all
the studied FAs was comparable to the unsaturated FAs, so that BR al-
most did not bind to 99-HSA. This was also conﬁrmed by theUV–Vis ab-
sorption and ﬂuorescence emission spectra. The ECD spectra in the
presence of liposomes showed an enantioselective binding of BR and
the spectral envelope reﬂected BR binding both to the liposomes and
to the primary and secondary sites of 99-HSA. The observed results sug-
gested that the effect of the unsaturated acids in the mixture was more
signiﬁcant than the effect of the saturated acids. Generally, the spectra
were most similar to the spectra measured with AA, which conﬁrms
the importance of this acid in human plasma. Overall, the presence of
saturated and unsaturated FAs either in combination or alone strongly
restricts the BR binding to 99-HSA and supports its binding to the
model membranes. Although the used FAs are among the most abun-
dant in the blood plasma, they are not present in the same concentra-
tions. This probably caused the discrepancy between the spectra for
FA-HSA (Fig. 3) and for the FA mixture (Fig. 8). It is probable that
under physiological conditions, the unsaturated FAs do not inﬂuence
BR binding to HSA to such an extent.
4. Conclusions
In this study, the effect of model membranes on the BR binding to
HSA was demonstrated. The results obtained in the presence of highly
puriﬁed 99-HSA suggested that at low BR concentrations, typical of
the blood plasma of a healthy human, BR preferred to bind to the prima-
ry binding site of 99-HSA. For the increased concentrations of BR, simu-
lating pathologic states, a minor binding of BR to the liposomes was
observed but a strong preference for the binding sites of 99-HSA was
documented.
However, for the non-puriﬁed FA-HSA, a remarkable effect of both
the DMPC and sphingomyelin liposomes on the BR binding to FA-HSA
was manifested. For the DMPC liposomes, even competition with the
primary binding site of HSA occurred and the combined effect of FAs
and the DMPC liposomes caused changes in the conformation of
bound BR. For higher BR concentrations, the BR binding to both the pri-
mary and secondary sites of FA-HSA and the DMPC liposomes was
observed. On the other hand, the effect of the sphingomyelin liposomes
on the BR binding to the primary site of FA-HSA was negligible
Fig. 7. The ECD (top) andUV–Vis spectra (bottom) of BRwith AA and 99-HSA (A) and in the presence of theDMPC (B) or sphingomyelin (SPM) liposomes (C)measured for the BR:99-HSA
ratios from 1:1 to 5:1. The spectra of 99-HSAwith BR (ratio 1:1, all panels), 99-HSAwith AA (A) and with the DMPC (B) or sphingomyelin (SPM) liposomes (C) are also shown. The con-
centration of 99-HSAwas 1 × 10−5M, that of the liposomes 1 × 10−3M and the BR concentrationwas given by the BR:99-HSA ratio andwas in the region of 1 × 10−5M–5 × 10−5M. The
concentration of AA was 1 × 10−4 M.
Fig. 8. The ECD (top) and UV–Vis spectra (bottom) of BR with MA, PA, SA, LA, OA and AA mixture (1:1:1:1:1:1) and 99-HSA (A) and in the presence of the DMPC (B) or sphingomyelin
(SPM) liposomes (C) measured for the BR:99-HSA ratios from 1:1 to 5:1. The spectra of 99-HSA with BR (ratio 1:1, all panels), 99-HSA with MA, PA, SA, LA, OA and AA mixture
(1:1:1:1:1:1) (A) and with the DMPC (B) or sphingomyelin (SPM) liposomes (C) are also shown. The concentration of 99-HSA was 1 × 10−5 M, that of the liposomes 1 × 10−3 M and
the BR concentration was given by the BR:99-HSA ratio and was in the region of 1 × 10−5 M–5 × 10−5 M. The concentration of MA, PA, SA, LA, OA and AA mixture (1:1:1:1:1:1) was
1 × 10−4 M.
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liposomes.
The observed effects of the combination of the liposomes and FAs
presented in the FA-HSA sample were explained with the study of
liposomic solutions with the individual FAs and 99-HSA. We may con-
clude that the effect of the added FAs on the BR binding to 99-HSA
and model membranes was stronger than for the FAs presented as a
component of FA-HSA. The saturated FAs and their mixture inﬂuenced
the BR binding to 99-HSA and liposomes in a similar way as the FAs
from FA-HSA. Nevertheless, a stronger effect for lower concentrations
of BRwas observed. The effect of unsaturated FAs, which aremore com-
mon in the human blood plasma, was quite unexpected and not very
similar to what was observed for FA-HSA. They interacted with BR and
prevented it from interacting with both 99-HSA and liposomes. Only
in the presence of AA, BR interacted enantioselectively with the
liposomes and 99-HSA.
As the spectra observed in the presence of both the DMPC and
sphingomyelin liposomeswith FA-HSAwere similar to the spectramea-
sured in the presence of the combination of all the FAs, we suggest that
all of the different types of FAs contribute in a different extent. When
FAsnaturally occur in theHSA structure (FA-HSA), they do not inﬂuence
its structure so gravely and do not disturb BR binding as much as when
we added them to the solution.Most likely, theywere not released from
the FA-HSA structure so effortlessly in order to interact with BR and pre-
vent it from binding to FA-HSA. This also showed that the effect of FAs
which are found in the blood plasma and of FAs which are transported
as bound to HSA is different.
Hence, we may conclude that primarily the saturated FAs have an
impact on the BR interactions in the solutionswith FA-HSA. Also as a re-
sult of the FA occurrence in the blood plasma and in the natural struc-
ture of HSA, BR may possibly bind to cell membranes even though it is
primarily bound to HSA. The probability of this increases with BR con-
centration and the presence of saturated FAs and is dependent on the
type of lipids in the membranes. Therefore, we conﬁrmed that, at in-
creased BR concentrations or during its accumulation in tissues, BR
binding to cell membranes is possible and, hence, is also the supposed
neurotoxicity of BR.
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